22.6%的EGFR突变NSCLC在初次诊断为转移性NSCLC合并LM,22%的ALK基因融合NSCLC在初次诊断为转移性NSCLC合并LM[3, 21]。随着酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs)的广泛应用,驱动基因阳性NSCLC患者LM生存期明显延长[3, 21]。. The gene discussed is ALK; the disease is non-small cell lung carcinoma.